肺动脉高压合并铁缺乏的现状、机制、治疗研究进展  

Research Progress on the Status,Mechanism,and Treatment of Pulmonary Arterial Hypertension Complicated with Iron Deficiency

作　　者：任韬婕 戴海龙[1] REN Taojie;DAI Hailong(Department of Cardiology/Key Laboratory of Cardiovascular Disease of Yunnan Province/Clinical Medicine Center for Cardiovascular Disease of Yunnan Province,Yan'an Hospital Affiliated to Kunming Medical University,Kunming 650051,China)

机构地区：[1]昆明医科大学附属延安医院心血管内科、云南省心血管疾病重点实验室、云南省心脏疾病临床医学中心,云南省昆明市650051

出　　处：《实用心脑肺血管病杂志》2024年第3期22-26,共5页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

基　　金：国家自然科学基金资助项目(82060018,81700438);云南省科技计划项目(202301AY070001-300,202101AS070043,202102AA310003-7)。

摘　　要：肺动脉高压(PAH)属于毛细血管前肺高血压(PH),是一种以肺动脉压力和肺血管阻力升高为特征的肺血管疾病,常引起临床血流动力学改变,严重者可导致右心衰竭甚至死亡。部分研究表明,铁缺乏(ID)普遍存在于多种类型PH患者中,其会降低患者的运动耐量及生活质量,而适当的补铁治疗可改善患者预后。但目前国内外关于PAH合并ID的研究较少。基于此,本文综述了PAH合并ID的现状、机制、治疗研究进展,并指出未来可进一步加大PAH与ID之间的病理生理机制研究,以期为PAH提供新的治疗靶点。Pulmonary arterial hypertension(PAH)belongs to precapillary pulmonary hypertension(PH),which is a pulmonary vascular disease characterized by increased pulmonary arterial pressure and pulmonary vascular resistance.It often causes clinical hemodynamic changes,and can lead to right heart failure or even death in severe cases.Some studies have shown that iron deficiency(ID)is commonly present in various types of PH patients,which can reduce their exercise tolerance and quality of life,and appropriate iron supplementation treatment can improve patients'prognosis.However,there are few studies on PAH combined with ID at home and abroad.Based on this,this article reviews the current situation,mechanism,and therapeutic research progress of PAH combined with ID,and points out that the pathophysiological mechanism between PAH and ID can be further studied in the future,in order to provide new therapeutic targets for PAH.

关 键 词：肺动脉高压 铁缺乏症 综述 

分 类 号：R541.5[医药卫生—心血管疾病]